A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
Indivior Pharmaceuticals, Inc. and its subsidiaries (together, "Indivior" or the "Company") is the market leader in long-acting injectable medications for opioid use disorder (OUD). Indivior is focused on delivering evidence-based pharmacotherapies for OUD and is committed to advancing the neurobiological understanding of OUD as a chronic, relapsing, but treatable brain disease. For more than 25 years, Indivior has led innovation in addiction medicine, developing differentiated therapeutic solutions that support long-term patient recovery, expand access to care, and drive sustainable value for patients, healthcare systems and stockholders. Headquartered in the U.S. in Richmond, Virginia, Indivior and its portfolio of products is available primarily in the U.S. with additional products available in Canada, Australia, France, and Germany.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 1.2B | 1.2B | 1.2B | 1.1B | 901M | 791M |
| Net Income | 210M | 210M | 7.0M | -126M | -44M | 205M |
| EPS | $1.67 | $1.64 | $0.05 | $-0.92 | $-0.32 | $1.35 |
| Free Cash Flow | -93M | -93M | 7.0M | -308M | -9.0M | 349M |
| ROIC | 16.3% | 18.3% | 1.5% | -6.8% | -83.0% | 149.5% |
| Gross Margin | 80.2% | 80.2% | 67.3% | 84.1% | 83.1% | 83.9% |
| Debt/Equity | 0.00 | -3.58 | -1.11 | -1.55 | -0.20 | 0.01 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | 262M | 262M | 38M | -152M | -81M | 213M |
| Operating Margin | 21.1% | 21.1% | 3.2% | -13.9% | -9.0% | 26.9% |
| ROE | 0.0% | -96.6% | -2.7% | 126.6% | -83.0% | 143.9% |
| Shares Outstanding | 125M | 128M | 140M | 137M | 138M | 152M |
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 791M | 901M | 1.1B | 1.2B | 1.2B | 1.2B |
| Gross Margin | 83.9% | 83.1% | 84.1% | 67.3% | 80.2% | 80.2% |
| R&D | 52M | 72M | 106M | 107M | 97M | 97M |
| SG&A | 431M | 469M | 565M | 612M | 634M | 634M |
| EBIT | 213M | -81M | -152M | 38M | 262M | 262M |
| Op. Margin | 26.9% | -9.0% | -13.9% | 3.2% | 21.1% | 21.1% |
| Net Income | 205M | -44M | -126M | 7.0M | 210M | 210M |
| Net Margin | 25.9% | -4.9% | -11.5% | 0.6% | 16.9% | 16.9% |
| Non-Recurring | 0 | 0 | 0 | 61M | 146M | 146M |
| Returns on Capital | ||||||
| ROIC | 149.5% | -83.0% | -6.8% | 1.5% | 18.3% | 16.3% |
| ROE | 143.9% | -83.0% | 126.6% | -2.7% | -96.6% | 0.0% |
| ROA | 21.9% | -2.4% | -7.1% | 0.5% | 16.7% | 14.8% |
| Cash Flow | ||||||
| Op. Cash Flow | 353M | -4.0M | -300M | 36M | -27M | -27M |
| Free Cash Flow | 349M | -9.0M | -308M | 7.0M | -93M | -93M |
| Owner Earnings | 338M | -36M | -336M | -4.0M | -63M | -63M |
| CapEx | 4.0M | 5.0M | 8.0M | 29M | 66M | 66M |
| Maint. CapEx | 15M | 16M | 15M | 16M | 10M | 10M |
| Growth CapEx | 0 | 0 | 0 | 13M | 56M | 56M |
| D&A | 15M | 16M | 15M | 16M | 10M | 10M |
| CapEx/OCF | 1.1% | N/A | N/A | 80.6% | N/A | 0.0% |
| Capital Allocation | ||||||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 90M | 33M | 173M | 11M | 11M |
| Buyback Yield | N/A | N/A | 1.6% | 10.0% | 0.2% | 0.3% |
| Stock-Based Comp | N/A | 16M | 21M | 24M | 26M | 26M |
| Debt Repayment | 236M | 3.0M | 12M | 240M | 17M | 17M |
| Balance Sheet | ||||||
| Net Debt | -1.1B | -771M | -124M | 55M | 156M | -123M |
| Cash & Equiv. | 1.1B | 774M | 316M | 319M | 195M | 445M |
| Long-Term Debt | N/A | 0 | 237M | 315M | 290M | 290M |
| Debt/Equity | 0.01 | -0.20 | -1.55 | -1.11 | -3.58 | 0.00 |
| Interest Coverage | 7.9 | -4.3 | -5.6 | 1.3 | 6.9 | 6.9 |
| Equity | 203M | -15M | -184M | -337M | -98M | -207M |
| Total Assets | 1.8B | 1.8B | 1.8B | 1.3B | 1.2B | 1.4B |
| Total Liabilities | 1.6B | 1.8B | 1.9B | 1.7B | 1.3B | 1.6B |
| Intangibles | N/A | N/A | 8.0M | 4.0M | 0 | 0 |
| Retained Earnings | 1.4B | 1.3B | 1.2B | -443M | -243M | -243M |
| Working Capital | N/A | N/A | -24M | -97M | -262M | -262M |
| Current Assets | N/A | N/A | 1.3B | 827M | 652M | 652M |
| Current Liabilities | N/A | N/A | 1.3B | 924M | 914M | 914M |
| Per Share Data | ||||||
| EPS | 1.35 | -0.32 | -0.92 | 0.05 | 1.64 | 1.67 |
| Owner EPS | 2.23 | -0.26 | -2.45 | -0.03 | -0.49 | -0.50 |
| Book Value | 1.34 | -0.11 | -1.34 | -2.41 | -0.77 | -1.66 |
| Cash Flow/Share | 2.32 | -0.03 | -2.19 | 0.26 | -0.21 | 1.76 |
| Dividends/Share | N/A | N/A | N/A | N/A | N/A | 0.00 |
| Shares Out. | 151.9M | 137.5M | 137.0M | 140.0M | 128.0M | 124.9M |
| Valuation | ||||||
| P/E Ratio | 12.8 | N/A | N/A | 247.6 | 22.1 | 19.8 |
| P/FCF | 7.5 | N/A | N/A | 247.6 | N/A | N/A |
| EV/EBIT | 7.1 | N/A | N/A | 46.4 | 18.3 | 15.2 |
| Price/Book | 12.9 | 60.2 | N/A | N/A | N/A | N/A |
| Price/Sales | 2.3 | 2.8 | 2.5 | 1.7 | 1.9 | 3.3 |
| FCF Yield | 13.3% | -0.3% | -14.9% | 0.4% | -2.0% | -2.3% |
| Market Cap | 2.6B | 3.1B | 2.1B | 1.7B | 4.6B | 4.1B |
| Avg. Price | 11.81 | 18.11 | 20.29 | 14.67 | 18.33 | 32.97 |
| Year-End Price | 17.25 | 22.00 | 15.10 | 12.38 | 36.21 | 32.97 |
Indivior Pharmaceuticals, Inc. passes 4 of 9 quality checks, suggesting mixed fundamentals.
Indivior Pharmaceuticals, Inc. trades at 20.1x trailing earnings, compared to its 15-year median P/E of 17.4x, suggesting it is currently Fair relative to its historical range. The company's 5-year average ROIC is 15.9% with a gross margin of 79.7%. Total shareholder yield (buybacks) is 0.3%. At current prices, the estimated annualized return to fair value is -38.5%.
Indivior Pharmaceuticals, Inc. (INDV) has a current P/E ratio of 20.1, compared to its historical median P/E of 17.4. The stock is currently considered Fair based on its historical valuation range.
Indivior Pharmaceuticals, Inc. (INDV) has a 5-year average return on invested capital (ROIC) of 15.9%. This indicates strong capital allocation and a potential competitive advantage.
Indivior Pharmaceuticals, Inc. (INDV) has a market capitalization of $4.1B. It is classified as a mid-cap stock.
Indivior Pharmaceuticals, Inc. (INDV) does not currently pay a regular dividend. However, the company returns capital to shareholders through share buybacks, with a buyback yield of 0.27%.
Based on historical P/E analysis, Indivior Pharmaceuticals, Inc. (INDV) appears fair. The current P/E of 20.1 is 15% above its historical median of 17.4. The estimated fair value CAGR (P/E method) is -12.7%.
Indivior Pharmaceuticals, Inc. (INDV) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
Indivior Pharmaceuticals, Inc. (INDV) reported annual revenue of $1.2 billion in its most recent fiscal year, based on SEC EDGAR filings.
Indivior Pharmaceuticals, Inc. (INDV) has a net profit margin of 16.9%. This is a healthy margin.
Indivior Pharmaceuticals, Inc. (INDV) generated $-93 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
Indivior Pharmaceuticals, Inc. (INDV) reported earnings per share (EPS) of $1.64 in its most recent fiscal year.
Indivior Pharmaceuticals, Inc. (INDV) has a return on equity (ROE) of -96.6%. A negative ROE may indicate losses or negative equity.
Indivior Pharmaceuticals, Inc. (INDV) has a 5-year average gross margin of 79.7%. This high margin suggests strong pricing power and a potential competitive moat.
The Ledger Terminal provides 5 years of financial data for Indivior Pharmaceuticals, Inc. (INDV), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Indivior Pharmaceuticals, Inc. (INDV) has a book value per share of $-0.77, based on its most recent annual SEC filing.